Free Trial

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics logo
$72.88
+0.34 (+0.47%)
(As of 11/1/2024 ET)

Viking Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
11

Based on 11 Wall Street analysts who have issued ratings for Viking Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 10 have given a buy rating, and 1 has given a strong buy rating for VKTX.

Consensus Price Target

$108.60
49.01% Upside
According to the 11 analysts' twelve-month price targets for Viking Therapeutics, the average price target is $108.60. The highest price target for VKTX is $138.00, while the lowest price target for VKTX is $80.00. The average price target represents a forecasted upside of 49.01% from the current price of $72.88.
Get the Latest News and Ratings for VKTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Viking Therapeutics and its competitors.

Sign Up

VKTX Analyst Ratings Over Time

TypeCurrent Forecast
11/3/23 to 11/2/24
1 Month Ago
10/4/23 to 10/3/24
3 Months Ago
8/5/23 to 8/4/24
1 Year Ago
11/3/22 to 11/3/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$108.60$108.60$111.78$30.25
Forecasted Upside49.01% Upside69.40% Upside110.70% Upside186.73% Upside
Consensus Rating
Buy
Buy
Buy
Buy

VKTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VKTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Viking Therapeutics Stock vs. The Competition

TypeViking TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.09
2.79
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside49.01% Upside15,964.09% Upside10.57% Upside
News Sentiment Rating
Neutral News

See Recent VKTX News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/24/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$90.00 ➝ $90.00+49.03%
9/25/2024Oppenheimer
3 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$138.00 ➝ $138.00+113.42%
9/12/2024Morgan Stanley
3 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00+72.61%
9/11/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$80.00+46.39%
7/25/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Seedhouse
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetStrong-Buy ➝ Strong-Buy$116.00 ➝ $118.00+76.67%
6/17/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$120.00 ➝ $120.00+135.71%
6/4/2024Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$120.00 ➝ $120.00+117.08%
3/26/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$100.00 ➝ $125.00+47.58%
3/15/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$80.00+23.36%
3/7/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$110.00+20.64%
2/23/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
5/30/2023Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Dupuis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
3/29/2023Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$15.00 ➝ $19.00+18.53%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:27 AM ET.


VKTX Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Viking Therapeutics is $108.60, with a high forecast of $138.00 and a low forecast of $80.00.

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VKTX shares.

According to analysts, Viking Therapeutics's stock has a predicted upside of 49.01% based on their 12-month stock forecasts.

Viking Therapeutics has been rated by research analysts at HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, and Oppenheimer in the past 90 days.

Analysts like Viking Therapeutics more than other "medical" companies. The consensus rating for Viking Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VKTX compares to other companies.


This page (NASDAQ:VKTX) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners